Resveratrol as an adjunct therapy in cyclophosphamide-treated MCF-7 cells and breast tumor explants.
Cancer Sci. 2011 Jan 28. Epub 2011 Jan 28. PMID: 21276137
Tissue and Cell Culture Unit, TCCU, Central Drug Research Institute, CSIR, Lucknow-226001, India Genotoxicity Laboratory, Toxicology Division, Central Drug Research Institute, CSIR, Lucknow-226001, India. Lucknow Cancer Institute, Lucknow- 226 001, India Histopathology Laboratory, Toxicology Division, Central Drug Research Institute, CSIR, Lucknow-226001, India. Enviornmental Microbiology Laboratory, Indian Institute of Toxicology Research, Lucknow-226001, India. Department of Biochemistry,
Cyclophosphamide (CPA) has efficacy as a breast cancer therapy. However, toxicity to CPA limits its clinical applications. Hence is the need to develop compounds that may be combined with it to improve the efficacy and overcome toxicity. We showed previously that Resveratrol (RES), a chemopreventive agent, increased the growth inhibitory effect of CPA treated MCF-7 cells. Presently, we have explored the molecular basis of 5mM CPA, 50μM RES as combination on cell-cycle progression, apoptosis and oxidative stress in MCF-7 breast cancer cells. Efficacy of the combination was also evaluated in a serum-free tumor explant culture model. The combination elicited enhanced anti-proliferative action coupled with differential expressionof cell-cycle, apoptosis, and stress factors. Furthermore, co-treatment superiority in histologically validated ER positive breast cancer explants suggests that this combination may be a worthy future clinical anti-neoplastic regimen.